Skip to Content
Stock Analyst Update

Keeping Our Moderna FVE After In-Line Q1 Progress

Moderna shipped 102 million doses of mRNA-1273 in the first quarter, and reported sales of the vaccine of $1.7 billion in the quarter tracked closely with our $1.9 billion forecast.

Mentioned:

We're maintaining our $117 fair value estimate for Moderna (MRNA) following the release of first-quarter results and updated data for its COVID-19 vaccine program that largely fit with our prior assumptions. Moderna shipped 102 million doses of mRNA-1273 in the first quarter, and reported sales of the vaccine of $1.7 billion in the quarter tracked closely with our $1.9 billion forecast. Advance purchase agreements for 845 million doses (corresponding to $19.2 billion in sales) are now in place for 2021. We've slightly raised our full-year estimate to match this (from our prior estimate of $18.8 billion), but we've also slightly raised our estimates for capital expenditures to factor in additional investment in manufacturing capacity, leading to a neutral impact on our valuation. We continue to think that Moderna is still in the process of building a moat based on its mRNA technology leadership.

We're still assessing the competitive landscape in this novel field of vaccine and drug development, and while COVID-19 vaccine mRNA-1273 remains central to investors during the pandemic, we're focused on Moderna's ability to create novel, differentiated vaccines in CMV (entering phase 3 this year), Zika (entering phase 2), and several other phase 1 respiratory virus programs, including RSV and flu. Beyond vaccines, Moderna is continuing to enroll studies in oncology, cardiology, and rare diseases, which could create a significant new market for therapeutic mRNA. 

Morningstar Premium Members gain exclusive access to our full analyst reports, including fair value estimates, bull and bear breakdowns, and risk analyses. Not a Premium Member? Get this and other reports immediately when you try Morningstar Premium free for 14 days.

Karen Andersen does not own shares in any of the securities mentioned above. Find out about Morningstar’s editorial policies.

Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data.

We’d like to share more about how we work and what drives our day-to-day business.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions. Our investment management business generates asset-based fees, which are calculated as a percentage of assets under management. We also sell both admissions and sponsorship packages for our investment conferences and advertising on our websites and newsletters.

How we use your information depends on the product and service that you use and your relationship with us. We may use it to:

  • Verify your identity, personalize the content you receive, or create and administer your account.
  • Provide specific products and services to you, such as portfolio management or data aggregation.
  • Develop and improve features of our offerings.
  • Gear advertisements and other marketing efforts towards your interests.

To learn more about how we handle and protect your data, visit our privacy center.

Maintaining independence and editorial freedom is essential to our mission of empowering investor success. We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view. We also respect individual opinions––they represent the unvarnished thinking of our people and exacting analysis of our research processes. Our authors can publish views that we may or may not agree with, but they show their work, distinguish facts from opinions, and make sure their analysis is clear and in no way misleading or deceptive.

To further protect the integrity of our editorial content, we keep a strict separation between our sales teams and authors to remove any pressure or influence on our analyses and research.

Read our editorial policy to learn more about our process.